Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models-Reference-Cited by-同舟云学术

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Published:2015-08 Issue:8 Volume:17 Page:661-670
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Rios-Doria Jonathan,Durham Nicholas,Wetzel Leslie,Rothstein Raymond,Chesebrough Jon,Holoweckyj Nicholas,Zhao Wei,Leow Ching Ching,Hollingsworth Robert

Publisher

Elsevier BV

Subject

Cancer Research

Reference38 articles.

1. Agonist antibodies to TNFR molecules that costimulate T and NK cells;Melero;Clin Cancer Res,2013

2. At the bedside: CTLA-4– and PD-1–blocking antibodies in cancer immunotherapy;Callahan;J Leukoc Biol,2013

3. Checkpoint modulation in melanoma: an update on ipilimumab and future directions;Page;Curr Oncol Rep,2013

4. Immune modulation in cancer with antibodies;Page;Annu Rev Med,2014

5. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer;Guo;PLoS One,2014

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future;Medicinal Research Reviews;2024-06-17

2. Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches;Acta Pharmaceutica Sinica B;2024-06

3. Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD‐1 by NGLY1;FEBS Letters;2024-05-23

4. Beneficial Effects of Oral Carbon Monoxide on Doxorubicin‐Induced Cardiotoxicity;Journal of the American Heart Association;2024-05-07

5. Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC;Current Pharmaceutical Design;2024-05